Spyre Therapeutics (SYRE) Is Up 32.7% After $403 Million Equity Raise On Positive Phase 2 Data [Yahoo! Finance]
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: Yahoo! Finance
The company is now using its SKYLINE platform to test multiple monotherapy and combination regimens across six investigational agents, aiming to clarify how SPY001 and related antibodies might fit into the ulcerative colitis treatment landscape. With SPY001's Phase 2 efficacy signal now in hand, we'll examine how this platform trial progress could reshape Spyre's investment narrative. This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality What Is Spyre Therapeutics' Investment Narrative? For Spyre, the core belief is that its antibody platform can turn today's promising signals in ulcerative colitis and immune disease into a clinically and commercially relevant portfolio, despite zero revenue and ongoing losses. The Phase 2 SKYLINE data for SPY001, with meaningful remission and endoscopic outcomes, helped reframe the story around “best-in-class” potential, and the upsized US$403.0 million follow-on at US$62 per share g
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics (SYRE) had its price target raised by JonesTrading from $64.00 to $95.00. They now have a "buy" rating on the stock.MarketBeat
- Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 MillionGlobeNewswire
- Spyre Therapeutics prices upsized $403M stock deal; gross proceeds exceed initial $300M goal [Seeking Alpha]Seeking Alpha
- Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common StockGlobeNewswire
- Spyre Therapeutics (SYRE) had its price target raised by Robert W. Baird from $65.00 to $90.00. They now have an "outperform" rating on the stock.MarketBeat
SYRE
Earnings
- 11/4/25 - Beat
SYRE
Sec Filings
- 4/16/26 - Form 8-K
- 4/16/26 - Form 424B5
- 4/13/26 - Form 424B5
- SYRE's page on the SEC website